Mei Pharma Stock Performance
| MEIP Stock | USD 2.87 0.10 3.61% |
MEI Pharma has a performance score of 3 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.17, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning MEI Pharma are expected to decrease at a much lower rate. During the bear market, MEI Pharma is likely to outperform the market. MEI Pharma now secures a risk of 2.67%. Please verify MEI Pharma downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if MEI Pharma will be following its current price movements.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in MEI Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak forward indicators, MEI Pharma may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
Actual Historical Performance (%)
One Day Return 2.8 | Five Day Return 4.29 | Year To Date Return 12.47 | Ten Year Return (96.30) | All Time Return (99.97) |
Last Split Factor 1:20 | Dividend Date 2023-12-06 | Ex Dividend Date 2023-11-16 | Last Split Date 2023-04-17 |
1 | MEI Pharma Now Covered by Analysts at StockNews.com | 11/08/2024 |
2 | MEI Pharma Coverage Initiated at StockNews.com | 11/27/2024 |
3 | Acquisition by White Christine Anna of 50000 shares of MEI Pharma at 2.95 subject to Rule 16b-3 | 12/20/2024 |
| Begin Period Cash Flow | 16.9 M | |
| Free Cash Flow | -50.5 M |
MEI |
MEI Pharma Relative Risk vs. Return Landscape
If you would invest 275.00 in MEI Pharma on October 22, 2024 and sell it today you would earn a total of 12.00 from holding MEI Pharma or generate 4.36% return on investment over 90 days. MEI Pharma is currently generating 0.1041% in daily expected returns and assumes 2.6714% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than MEI, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MEI Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MEI Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MEI Pharma, and traders can use it to determine the average amount a MEI Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.039
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | MEIP | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.67 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average MEI Pharma is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MEI Pharma by adding it to a well-diversified portfolio.
MEI Pharma Fundamentals Growth
MEI Stock prices reflect investors' perceptions of the future prospects and financial health of MEI Pharma, and MEI Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MEI Stock performance.
| Return On Equity | 0.62 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | (19.24 M) | ||||
| Shares Outstanding | 6.66 M | ||||
| Price To Earning | 30.29 X | ||||
| Price To Book | 0.77 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 65.3 M | ||||
| Gross Profit | 49.33 M | ||||
| EBITDA | 26.38 M | ||||
| Net Income | 17.78 M | ||||
| Cash And Equivalents | 153.25 M | ||||
| Cash Per Share | 1.15 X | ||||
| Total Debt | 8.36 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | 4.96 X | ||||
| Cash Flow From Operations | (50.47 M) | ||||
| Earnings Per Share | (6.99) X | ||||
| Market Capitalization | 19.11 M | ||||
| Total Asset | 41.38 M | ||||
| Retained Earnings | (388.22 M) | ||||
| Working Capital | 32.41 M | ||||
| Current Asset | 46.75 M | ||||
| Current Liabilities | 5.51 M | ||||
About MEI Pharma Performance
Assessing MEI Pharma's fundamental ratios provides investors with valuable insights into MEI Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MEI Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.39 | 0.41 | |
| Return On Capital Employed | 0.40 | 0.42 | |
| Return On Assets | 0.39 | 0.41 | |
| Return On Equity | 0.48 | 0.51 |
Things to note about MEI Pharma performance evaluation
Checking the ongoing alerts about MEI Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MEI Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MEI Pharma has high likelihood to experience some financial distress in the next 2 years | |
| MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15. |
- Analyzing MEI Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MEI Pharma's stock is overvalued or undervalued compared to its peers.
- Examining MEI Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MEI Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MEI Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MEI Pharma's stock. These opinions can provide insight into MEI Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.